Market Research Report
Market Access Impact (US) [RA]
|Published by||FirstWord||Product code||593142|
Delivery time: 1-2 business days
|Market Access Impact (US) [RA]|
|Published: November 1, 2017||Content info:||
Who wins and loses when brands struggle with cost barriers and limited market access?
Market barriers affect just over 20 percent of rheumatoid arthritis (RA) prescriptions in the US. High costs and limited formulary access are preventing rheumatologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand?
Based on a survey of 100 rheumatologists, the report covers 11 major therapies from AbbVie, Amgen, Bristol-Myers Squibb, Janssen Biotech, Regeneron, Sanofi, Pfizer, Roche, and UCB. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.
Not your market? Click here to see the EU5 Edition.
Request sample pages
Biosimilars are struggling to have an impact. The most prescribed biosimilar is prescribed by just over a third of physicians, but removing barriers could double that.
Insight into 11 major RA drugs
Exploring Market Access Barriers
Market Access Impact: Rheumatoid Arthritis (US) explores key issues affecting drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 100 US-based rheumatologists, chosen from the largest community of validated physicians in the world.
We conducted the survey between November 3-9, 2017.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.